Stiff Person Syndrome with Subacute Onset and Rapid Progression: Next Step When First-Line Immunotherapy Has Not Achieved Improvement

Clinical Scenario

This protocol addresses patients with Stiff Person Syndrome presenting with a subacute onset of symptoms, a rapidly progressive course, and marked functional impairment — a clinical picture that demands structured escalation.

Subacute, rapidly progressive presentations represent an especially urgent subset requiring timely advancement beyond first-line measures when those measures fall short.

Prior Treatment — Inadequate Response

This is the next-line protocol for patients in whom first-line management did not produce adequate improvement. Prior treatment included:

Symptomatic treatment with intravenous midazolam or propofol
Tumour treatment or removal where an underlying tumour was present
First-line immunotherapy: plasma exchange (PLEX), intravenous immunoglobulin (IVIG), and intravenous methylprednisolone followed by oral methylprednisolone

The targets that were not adequately reached — reduction of stiffness and spasms, improved performance on timed activities, and a decrease in GlyR- and DPPX-antibody titres — define the escalation threshold that this protocol addresses.

Escalation Approach

When first-line immunotherapy is insufficient, this protocol employs a combination immunotherapy regimen — a targeted monoclonal antibody used alongside an immunosuppressive agent. The specific agents, their selection criteria, and the clinical decision algorithm are contained in the complete structured protocol.

Treatment Goals

Reduction of stiffness and spasms
Improved performance on timed activities
Decrease in GlyR- and DPPX-antibody titres

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/mdc3.12629

Subacute presentations, often rapidly progressive, are particularly seen in PERM.

Subacute onset, Rapid progression, Marked impairment

Treatment escalation e.g.: rituximab in combination with MP i.v. / cyclophosphamide

Such a combination therapy may for example involve rituximab and repeated high-dose steroid pulses, or a combination of rituximab and cyclophosphamide.

Such an assessment may for example involve the degree and distribution of stiffness, the response to a repeated standard stimulus such as a loud clap or a cold spray to the foot sole, and appropriate timed activities like walking a predefined distance, taking a flight of stairs or, in a patient with a stiff arm, the nine-hole-peg test.

Neuronal surface antibodies can provide additional, supportive information, as for example GlyR- and DPPX-antibody titres tend to correlate with disease severity, and their decrease may herald the immunotherapy being effective.

View source ↗